Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347576 | 0.83 | EPHX2 (0.40) | KDM4EGAAALDH1A1NPSR1HTT | |
| SCHEMBL1020008 | 0.82 | MEN1 (0.50) | KDM4EALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL347867 | 0.81 | TP53 (0.43) | HTT | |
| SCHEMBL347836 | 0.81 | HRH3 (0.39) | ALDH1A1NPSR1HTTSMN1; SMN2HRH3 | |
| SCHEMBL15310292 | 0.81 | MAPK1 (0.41) | KDM4EALDH1A1NPSR1HTTSMN1; SMN2 | |
| SCHEMBL348234 | 0.81 | L3MBTL1 (0.42) | ALDH1A1HRH3 | |
| Hydrochloric Acid SCHEMBL347498 | 0.80 | MAPK1 (0.41) | KDM4EALDH1A1NPSR1HTTSMN1; SMN2 | |
| SCHEMBL347913 | 0.80 | TSHR (0.43) | ALDH1A1NPSR1HTTSMN1; SMN2HRH3 | |
| SCHEMBL347202 | 0.78 | ALDH1A1 (0.54) | KDM4EGAAALDH1A1NPSR1HTT | |
| SCHEMBL348680 | 0.77 | ALDH1A1 (0.42) | KDM4EGAAALDH1A1SMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
| EP-2318368-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. Organon (NL) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010025179-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | KDM4E 3947/4885GAA 3420/4885ALDH1A1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.